The incidence of cardiovascular events and mortality strongly correlates with serum phosphate in individuals with CKD. The Npt2b transporter contributes to maintaining phosphate homeostasis in the setting of normal renal function, but its role in CKD-associated hyperphosphatemia is not well understood. Here, we used adenine to induce uremia in both Npt2b-deficient and wild-type mice. Compared w...

1.1 High mortality in dialysis patients Dialysis patients have extraordinarily high mortality rates. Cardiac disease is the major cause of death accounting for 43% of all-cause mortality among patients receiving hemodialysis and peritoneal dialysis [Henry et al., 2002; US Renal Data System Annual Data Report Bethesta, 2005]. In previous report, patients with end-stage kidney disease (chronic ki...

Objective This study was intended to explore the relationship between level of serum phosphate and prognosis in septic patients. Methods Data were obtained from public database, which divided into 2 subgroups according whether they complicated with chronic kidney disease. Initial values extracted patients on admission hospital. Propensity score-matched analysis performed. The hypophosphatemia, ...

introduction: electrolyte imbalances are very common among crushed earthquake victims but there is not enough data regarding their trend of changes. the present study was designed to evaluate the trend of changes in sodium, calcium, and phosphorus ions among crush syndrome patients. methods: in this retrospective cross-sectional study, using the database of bam earthquake victims, which was dev...

In patients on maintenance dialysis, hyperphosphatemia is a risk factor for mortality and hospitalization. Tenapanor an investigational, first-in-class, phosphate absorption inhibitor, providing novel, non-binder approach to treating hyperphosphatemia. The PHREEDOM study was long-term Phase 3 trial evaluating the safety efficacy of tenapanor treat in dialysis (hemo- or peritoneal dialysis). Thi...

Introduction: Chronic kidney disease (CKD) remains a global burden and catastrophic as about 697.5 million people suffering from it in 2017. About 42% of CKD mortality Indonesia is related to cardiovascular complications. Hyperphosphatemia, manifestation chronic disease-mineral bone disorder, could increase the risk mortality. Albuminuria has been proven inhibit compensatory mechanisms for hype...

Hyperphosphatemia is an independent risk factor for mortality and cardiovascular events in patients with chronic kidney disease (CKD). For patients who cannot control their serum phosphate levels adequately with diet, agents that limit gastrointestinal phosphate uptake are indicated. The use of phosphate-binding agents has changed over the years as more is learned about the mechanisms that unde...